二甲双胍对接受前列腺癌外照射放疗的男性可能无保护作用
该研究纳入2000至2007年间在一家大型癌症中心接受根治性外照射放疗的前列腺癌患者2055例(其中113例服用二甲双胍),中位随访95.7个月,比较服用与未服用二甲双胍者的生化失败时间、转移检出时间、前列腺癌特异性死亡和总生存;体外实验用PC3细胞在H2O2诱导氧化应激后给予递增剂量二甲双胍,检测HIF1α表达和细胞存活。结果显示二甲双胍与转移检出时间、生化失败时间或总生存无关联,但在调整癌症风险和合并症后,服用二甲双胍联合雄激素剥夺治疗(ADT)的患者前列腺癌特异性死亡增加1.5倍(P=0.045)。
要点
- 服用二甲双胍与未服用者在生化失败时间、转移检出时间或总生存上无显著差异。
- 调整癌症风险和合并症后,二甲双胍联合ADT者前列腺癌特异性死亡增加1.5倍(P=0.045)。
- 体外高浓度100 μM二甲双胍未降低HIF1α表达,也未影响氧化应激下PC3细胞存活。
核心结论
- 在接受外照射放疗(联合或不联合ADT)的前列腺癌患者中,未发现二甲双胍使用与转移检出时间、生化失败时间或总生存之间存在关联。
- 体外低治疗浓度二甲双胍对HIF1α无影响,该观察或可解释二甲双胍在接受外照射放疗的前列腺癌男性中有效性证据不一致的现象。
- 作者认为,在该患者群体中抑制哺乳动物雷帕霉素靶蛋白-HIF1α通路可能需要更高、毒性更大的二甲双胍剂量。
研究设计与样本
- 研究纳入2000至2007年间在一家大型癌症中心接受根治性外照射放疗的前列腺癌患者,共2055例符合条件,其中113例服用二甲双胍,中位随访95.7个月。
- 采用竞争风险和Cox回归模型分析服用与未服用二甲双胍者的生化失败时间、转移检出时间、前列腺癌特异性死亡和总生存。
- 体外实验将基础HIF1α水平高的PC3细胞在H2O2诱导氧化应激后给予递增剂量二甲双胍,检测HIF1α表达和细胞存活。
主要发现
- 服用与未服用二甲双胍者在年龄、初始前列腺特异性抗原水平、Gleason评分、T分期、D'Amico风险分级或ADT持续时间上无差异。
- 二甲双胍治疗未使生化失败时间、转移检出时间或总生存出现明显改善,但调整癌症风险和合并症后,服用二甲双胍联合ADT者前列腺癌特异性死亡增加1.5倍(P=0.045)。
- 比较高剂量二甲双胍(>1 g/d)与低剂量二甲双胍(≤1 g)患者,转移时间或生化失败时间均无差异。
- 体外100 μM高浓度二甲双胍未降低HIF1α表达,也未影响暴露于氧化应激(H2O2)的PC3细胞存活。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether metformin reduces radio-resistance and increases survival in men undergoing external beam radiation therapy (EBRT) for prostate cancer (PCa), and to determine its effect on hypoxia inducible factor 1-α (HIF1α). PATIENTS AND METHODS: All patients treated with curative intent with EBRT for PCa at a major cancer centre between 2000 and 2007 were included in this study. The outcome measures of time to biochemical failure (BF), metastasis, PCa-specific mortality and overall survival (OS) were analysed in those taking metformin vs those not, using competing risk and Cox regression models. To determine metformin's effect on HIF1α expression and survival in vitro, PC3 cells with high basal HIF1α levels were subjected to increasing doses of metformin after H2 O2 -induced oxidative stress. RESULTS: A total of 2055 eligible cases, including 113 who were on metformin, were identified, with a median follow-up of 95.7 months. There were no differences in age, initial prostate-specific antigen level, Gleason score, T-stage, D'Amico risk class or duration of androgen deprivation therapy (ADT) between patients who were or were not on metformin. Treatment with metformin did not result in any apparent improvement in time to BF, time to metastasis detection or OS, but there was a 1.5-fold increase in PCa-specific deaths (P = 0.045) in patients on metformin and ADT when adjusted for cancer risk and comorbidities. When comparing patients on high-dose metformin (>1 g/d) with those on low-dose metformin (≤1 g), there was no difference in either time to metastases or time to BF. In vitro metformin at a high concentration of 100 μM did not reduce HIF1α expression, nor did metformin affect the PC3 cell survival when exposed to oxidative stress (H2 O2 ). CONCLUSIONS: No association was found between the use of metformin and time to metastasis detection, time to BF or OS in patients undergoing radiation therapy with or without ADT for PCa. In vitro, low therapeutic concentrations of metformin had no effect on HIF1α, and this observation could explain the conflicting evidence for the effectiveness of metformin in men undergoing EBRT for PCa. Higher, more toxic doses of metformin may be required to inhibit the mammalian target of rapamycin-HIF1α pathway in this patient group.
引用
- Ranasinghe WKB, Williams S, Ischia J, et al. Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer. BJU Int. 2019. PMID: 31012989. doi:10.1111/bju.14709
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。